패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처는 미국 증권의 예를 사용했습니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 Github에서 확인할 수 있습니다.

애널리스트 출처

Ryman Healthcare Limited 9 애널리스트 중 3 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Andrew Steele	Credit Suisse
Stephen Ridgewell	Deutsche Bank
Aaron Ibbotson	Forsyth Barr Group Ltd.

Ryman Healthcare 대차 대조표 상태

재무 상태 기준 확인 2/6

주요 정보

최근 재무 상태 업데이트

Is Ryman Healthcare (NZSE:RYM) Weighed On By Its Debt Load?

Here's Why Ryman Healthcare (NZSE:RYM) Has A Meaningful Debt Burden

Ryman Healthcare (NZSE:RYM) Has Debt But No Earnings; Should You Worry?

Is Ryman Healthcare (NZSE:RYM) Using Too Much Debt?

Recent updates

New major risk - Share price stability

New Leadership And Pricing Reforms Will Boost Aged Care

Ryman Healthcare Limited to Report Fiscal Year 2025 Results on May 29, 2025

New major risk - Shareholder dilution

Ryman Healthcare Limited has filed a Follow-on Equity Offering in the amount of NZD 1.000642 billion.

Price target decreased by 13% to NZ$5.17

New minor risk - Share price stability

High number of new directors

First half 2025 earnings released: EPS: NZ$0.14 (vs NZ$0.27 in 1H 2024)

Is Ryman Healthcare Limited (NZSE:RYM) Trading At A 42% Discount?

Consensus EPS estimates increase by 30%

Ryman Healthcare Limited to Report First Half, 2025 Results on Nov 28, 2024

Is Ryman Healthcare (NZSE:RYM) Weighed On By Its Debt Load?

Insider recently sold NZ$612k worth of stock

Are Investors Undervaluing Ryman Healthcare Limited (NZSE:RYM) By 47%?

Ryman Healthcare Limited, Annual General Meeting, Aug 01, 2024

Ryman Healthcare's (NZSE:RYM) Soft Earnings Don't Show The Whole Picture

Price target decreased by 17% to NZ$6.05

New major risk - Financial position

Full year 2024 earnings released: EPS: NZ$0.007 (vs NZ$0.50 in FY 2023)

Little Excitement Around Ryman Healthcare Limited's (NZSE:RYM) Earnings

Returns On Capital At Ryman Healthcare (NZSE:RYM) Paint A Concerning Picture

Ryman Healthcare Limited to Report Fiscal Year 2024 Results on May 27, 2024

Investor sentiment deteriorates as stock falls 17%

Ryman Healthcare Limited's (NZSE:RYM) P/E Is On The Mark

Here's Why Ryman Healthcare (NZSE:RYM) Has A Meaningful Debt Burden

Capital Allocation Trends At Ryman Healthcare (NZSE:RYM) Aren't Ideal

First half 2024 earnings released: EPS: NZ$0.27 (vs NZ$0.39 in 1H 2023)

Consensus EPS estimates fall by 12%

Ryman Healthcare Limited to Report First Half, 2024 Results on Nov 29, 2023

What Is Ryman Healthcare Limited's (NZSE:RYM) Share Price Doing?

Less than half of directors are independent

Ryman Healthcare (NZSE:RYM) Has Debt But No Earnings; Should You Worry?

Ryman Healthcare Limited, Annual General Meeting, Jul 27, 2023

Consensus EPS estimates increase by 22%

Ryman Healthcare Limited (NZSE:RYM) Shares Could Be 24% Below Their Intrinsic Value Estimate

Ryman Healthcare Limited to Report Fiscal Year 2023 Results on May 19, 2023

Price target decreased by 7.5% to NZ$7.50

Consensus EPS estimates fall by 37%

Investor sentiment deteriorates as stock falls 16%

Price target decreased by 17% to NZ$8.69

Price target decreased by 8.0% to NZ$9.82

Price target decreased by 7.8% to NZ$10.36

Investor sentiment improves as stock rises 15%

Insufficient new directors

Upcoming dividend of NZ$0.088 per share

Consensus forecasts updated

Investor sentiment deteriorated over the past week

First half 2023 earnings released: EPS: NZ$0.39 (vs NZ$0.56 in 1H 2022)

Ryman Healthcare Limited Announces Interim Dividend, Payable on December 16, 2022

Ryman Healthcare Limited to Report Q2, 2023 Results on Nov 18, 2022

Should You Think About Buying Ryman Healthcare Limited (NZSE:RYM) Now?

Ryman Healthcare Appoints Cheyne Chalmers as New Zealand CEO

Consensus revenue estimates increase by 15%

Full year 2022 earnings: Revenues exceed analyst expectations

Ryman Healthcare Limited, Annual General Meeting, Jul 28, 2022

Ryman Healthcare Limited to Report Fiscal Year 2022 Results on May 20, 2022

When Should You Buy Ryman Healthcare Limited (NZSE:RYM)?

Consensus forecasts updated

Now 21% undervalued after recent price drop

Consensus forecasts updated

What Is Ryman Healthcare Limited's (NZSE:RYM) Share Price Doing?

Independent Non-Executive Director recently bought NZ$99k worth of stock

Upcoming dividend of NZ$0.088 per share

Key Executive recently bought NZ$194k worth of stock

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investors Could Be Concerned With Ryman Healthcare's (NZSE:RYM) Returns On Capital

Is It Too Late To Consider Buying Ryman Healthcare Limited (NZSE:RYM)?

Is Ryman Healthcare (NZSE:RYM) Using Too Much Debt?

Full year 2021 earnings released: EPS NZ$0.85 (vs NZ$0.53 in FY 2020)

Independent Director recently bought NZ$297k worth of stock